Loading...
Loading...
VBLT| Name | Value |
|---|---|
| Revenues | 0.1M |
| Cost of Revenue | -0.0M |
| Gross Profit | 0.2M |
| Operating Expense | 3.4M |
| Operating I/L | -62.3M |
| Other Income/Expense | 59.0M |
| Interest Income | 0.1M |
| Pretax | -3.3M |
| Income Tax Expense | -0.0M |
| Net Income/Loss | -3.3M |
Vascular Biogenics Ltd. is a clinical stage biopharmaceutical company specializing in the development of therapeutics for cancer and immune-inflammatory diseases. The company's primary focus is on its lead product candidate, VB-111, a gene-based biologic currently in Phase III clinical trials for recurrent platinum-resistant ovarian cancer, with additional Phase II trials for recurrent glioblastoma and colorectal cancer. Vascular Biogenics is also developing VB-601 for various inflammatory indications and VB-611 for various solid tumors. The company's revenue is generated through the development and potential commercialization of these innovative therapeutics targeting newly formed blood vessels and monocyte migration.
